China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced receiving official approval from the Guangdong provincial Medical Products Administration bureau for its Jext pre-filled adrenaline auto-injector pen. The product is now permitted to be imported into the Greater Bay Area (GBA) as a clinically urgently needed product.
Product Details and Regulatory Milestones
Grand Pharma’s Jext auto-injector is a disposable automatic syringe containing a sterile adrenaline solution. It has been approved for marketing in 21 countries and regions, including Spain, the United Kingdom, France, Germany, and South Korea, with verified safety and efficacy. This approval marks a significant expansion of Jext’s market reach into the GBA, addressing urgent clinical needs.
Grand Pharma’s Pipeline and Market Presence
Grand Pharma boasts over 20 investigational products in the cardio-cerebrovascular first aid segment. The company’s first generic epinephrine injection (pre-filled) won market approval in China in July 2022, further solidifying its position in the emergency medical treatment space.-Fineline Info & Tech
